ADAPYHealthcareMicro-Cap
Adaptimmune Therapeutics PLC Insider Trading Activity
Every SEC Form 4 insider transaction reported for Adaptimmune Therapeutics PLC (ADAPY), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are ADAPY insiders buying or selling?
Adaptimmune Therapeutics PLC insiders reported 24 open-market buys ($240.3M) and 95 sells ($22.6M) across 119 Form 4 filings — a net buying position of $217.7M.
Source: SEC EDGAR Form 4
Key Statistics (as of Sep 3, 2025)
Total Form 4 filings
119
SEC EDGAR
Insider filers
26
Insider buys (24)
$240.3M
Insider sells (95)
$22.6M
Insider sentiment
Net buyingNet insider flow of $217.7M in net buying.
Recent ADAPY insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 3, 2025 | Gavin Wood | Chief Financial Officer | Sale | 96.0K | $0.01 | $950.4 |
| Aug 29, 2025 | William C Bertrand JR | Chief Operating Officer | Sale | 207.0K | $0.01 | $2.1K |
| Aug 19, 2025 | Ali Behbahani | Director | Sale | 19.5M | $0.01 | $229.2K |
| Jul 30, 2025 | EcoR1 Capital, LLC | 10% Owner | Sale | 64.1M | $0.11 | $6.9M |
| Jan 18, 2025 | Elliot Norry | Chief Medical Officer | Sale | 5.6K | $0.58 | $3.2K |
| Jan 18, 2025 | John Lunger | Chief Patient Supply Officer | Sale | 5.6K | $0.58 | $3.2K |
| Jan 18, 2025 | William C Bertrand JR | Chief Operating Officer | Sale | 5.6K | $0.58 | $3.2K |
| Jan 18, 2025 | Adrian Rawcliffe | Chief Executive Officer | Sale | 30.6K | $0.58 | $17.8K |
| Jan 15, 2025 | Adrian Rawcliffe | Chief Executive Officer | Sale | 59.6K | $0.58 | $34.6K |
| Jan 15, 2025 | Cintia Piccina | Chief Commercial Officer | Sale | 13.0K | $0.57 | $7.5K |
| Jan 15, 2025 | Elliot Norry | Chief Medical Officer | Sale | 22.2K | $0.58 | $12.9K |
| Jan 15, 2025 | John Lunger | Chief Patient Supply Officer | Sale | 19.5K | $0.58 | $11.4K |
| Jan 15, 2025 | William C Bertrand JR | Chief Operating Officer | Sale | 19.5K | $0.58 | $11.4K |
| Jun 18, 2024 | Cintia Piccina | Chief Commercial Officer | Sale | 24.5K | $0.93 | $22.8K |
| Jan 17, 2024 | Adrian Rawcliffe | Chief Executive Officer | Sale | 39.4K | $0.70 | $27.6K |
| Jan 17, 2024 | Elliot Norry | Chief Medical Officer | Sale | 20.6K | $0.69 | $14.1K |
| Jan 17, 2024 | John Lunger | Chief Patient Supply Officer | Sale | 22.8K | $0.70 | $15.9K |
| Jan 17, 2024 | William C Bertrand JR | Chief Operating Officer | Sale | 23.6K | $0.70 | $16.4K |
| Jan 12, 2024 | Elliot Norry | Chief Medical Officer | Sale | 11.8K | $0.85 | $10.0K |
| Jan 12, 2024 | William C Bertrand JR | Chief Operating Officer | Sale | 9.2K | $0.85 | $7.8K |
| Jan 12, 2024 | Adrian Rawcliffe | Chief Executive Officer | Sale | 29.2K | $0.85 | $24.7K |
| Jan 12, 2024 | John Lunger | Chief Patient Supply Officer | Sale | 9.2K | $0.85 | $7.8K |
| Sep 1, 2023 | Adrian Rawcliffe | Chief Executive Officer | Sale | 2.4K | $0.78 | $1.9K |
| Aug 1, 2023 | John Lunger | Chief Patient Supply Officer | Sale | 3.1K | $0.91 | $2.8K |
| Jul 10, 2023 | Garry E Menzel | Director | Sale | 47.7K | $0.91 | $43.4K |
Showing the 25 most recent of 119 Form 4 filings for Adaptimmune Therapeutics PLC.
Most active ADAPY insiders
- Adrian Rawcliffe23 filings
- John Lunger20 filings
- William C Bertrand JR17 filings
- Elliot Norry13 filings
- Cintia Piccina4 filings
Ask anything about ADAPY insider activity
Use Trabud's AI agent to query Adaptimmune Therapeutics PLC's Form 4 history in plain English — "Show me ADAPY CEO purchases this year" or compare it against any other ticker.
Open the AI agentADAPY insider trading FAQ
Are Adaptimmune Therapeutics PLC insiders buying or selling?
Across 119 SEC Form 4 filings, Adaptimmune Therapeutics PLC (ADAPY) insiders reported 24 open-market purchases totaling $240.3M and 95 sales totaling $22.6M. That is a net buying position of $217.7M.
How many insiders trade ADAPY stock?
26 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Adaptimmune Therapeutics PLC. The most recent filing was accepted on Sep 3, 2025.
Where does Trabud get ADAPY insider trading data?
All ADAPY insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.